ScreenerHero

ARDS Aridis Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · aridispharma.com
0.0001USD0.00%Mkt Cap: 4457 $P/E: —

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product can…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap4.46K USD
Enterprise Value4.81M USD
Revenue (TTM)22.36M USD
Gross Profit5.21M USD
Net Income (TTM)-30.37M USD
Revenue/Share0.69 USD
Last Price0.0001 USD
Fiscal Year EndDec 2022
MR QuarterSep 2023
Employees37
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.00
PEG—
EV/EBITDA-13.86
EV/Revenue0.22
P/S0.00
P/B-0.00
EPS (TTM)-0.16
EPS (Forward)-0.09
52W Range
0.00010% of range0.0500
52W High0.0500 USD
52W Low0.0001 USD
Profitability
Gross Margin23.28%
Oper. Margin-208.39%
EBITDA Margin-1.55%
Profit Margin-5.11%
ROE125.33%
ROA-206.68%
Growth
Revenue Growth4.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.13M USD
CapEx (TTM)82.00K USD
FCF Margin-73.28%
FCF Yield-367623.96%
Net Debt4.80M USD
Net Debt/EBITDA-13.85
Balance Sheet
Debt/Equity-0.25
Current Ratio0.23
Quick Ratio0.03
Book Value/Sh-0.27 USD
Cash/Share0.0010 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.44.57M
Float40.31M
Insiders0.00%
Institutions11.44%
Short Interest
Short Ratio1.5d
Short % Float8.23%
Short % Out.6.72%
Shares Short2.43M
Short (prev mo.)1.85M
Technical
SMA 500.0001 (-0.0%)
SMA 2000.0005 (-78.1%)
Beta3431.53
S&P 52W Chg16.45%
Avg Vol (30d)6.41K
Avg Vol (10d)3.78K
Technical Indicators
RSI (14)39.9
MACD-0.0000
MACD Signal-0.0000
MACD Hist.+0.0000
BB Upper0.0001 USD
BB Middle0.0001 USD
BB Lower0.0001 USD
BB Width0.00%
ATR (14)0.0001 USD
Vol Ratio (20d)4.40x